{"nctId":"NCT01425463","briefTitle":"A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects","startDateStruct":{"date":"2011-03"},"conditions":["Iron Deficiency Anemia"],"count":256,"armGroups":[{"label":"Ferrous (II) Glycine Sulphate Complex","type":"EXPERIMENTAL","interventionNames":["Drug: Ferrous (II) Glycine Sulphate Complex","Other: Placebo to Polyferose"]},{"label":"Polyferose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Polyferose","Other: Placebo to Ferrous (II) Glycine Sulphate Complex"]}],"interventions":[{"name":"Ferrous (II) Glycine Sulphate Complex","otherNames":["Ferro Sanol Duodenal"]},{"name":"Polyferose","otherNames":["Nifirex"]},{"name":"Placebo to Ferrous (II) Glycine Sulphate Complex","otherNames":[]},{"name":"Placebo to Polyferose","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* An iron deficiency anemia patient with Serum Ferritin \\< 12 ng/mL, serum Hb-values \\>60 and \\< 120 g/L in males, \\< 110 g/L in females\n\nExclusion Criteria:\n\n* With any Mal-absorption Syndrome\n* With a history of Thalassemia or Sickle Cell Anemia\n* With untreated concurrent Vitamin B12 or Folate deficiency at Baseline","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hemoglobin (Hb) From Baseline (Week 0) to Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.47","spread":"23.77"},{"groupId":"OG001","value":"31.92","spread":"21.82"}]}]}]},{"type":"SECONDARY","title":"Change in Hemoglobin (Hb) From Baseline (Week 0) to Week 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.29","spread":"13.60"},{"groupId":"OG001","value":"12.79","spread":"13.13"}]}]}]},{"type":"SECONDARY","title":"Change in Hemoglobin (Hb) From Baseline (Week 0) to Week 4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.37","spread":"19.63"},{"groupId":"OG001","value":"20.16","spread":"17.46"}]}]}]},{"type":"SECONDARY","title":"Change in Hemoglobin (Hb) From Baseline (Week 0) to Week 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.57","spread":"22.67"},{"groupId":"OG001","value":"28.33","spread":"20.90"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders at Week 12","description":"Responders are defined as having an increment of Hemoglobin (Hb) \\> 15 g/L and post-treatment Hb \\> 120 g/L (male) or \\> 110 g/L (female) at Visit 6 (Week 12).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":null},{"groupId":"OG001","value":"80.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":126},"commonTop":["Diarrhoea","Melaena","Abdominal pain","Nausea"]}}}